Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026 [Japanese Standards] (Consolidated) (Interim Review by Certified Public Accountants Completed)

Overview of Business Performance

During the cumulative consolidated third quarter period of the fiscal year ending March 2026, Mochida Pharmaceutical Co., Ltd. recorded net sales of JPY 87,487 million (up 8.4% YoY), operating income of JPY 7,526 million (up 3.9% YoY), ordinary income of JPY 8,346 million (up 9.2% YoY), and net income attributable to owners of parent of JPY 6,342 million (up 13.2% YoY). The pharmaceutical-related business increased sales YoY supported by growth in new drugs, while the healthcare business also saw an 8.2% increase in net sales compared to the previous year. Research and development expenses amounted to JPY 8,984 million, focusing on enhancing the drug discovery pipeline and incorporating new modalities.

Financial Condition and Future Outlook

Total assets amounted to JPY 182,220 million, and net assets were JPY 137,431 million, both increasing compared to the previous consolidated fiscal year-end. Meanwhile, the equity ratio was 75.4%, down from 81.6% YoY. The number of issued shares was 36,390,000 shares, and treasury shares totaled 940,091 shares, nearly unchanged from the previous year. The annual dividend forecast remains unchanged at JPY 80.00 per share. The full-year earnings guidance projects net sales of JPY 115,500 million (up 9.8% YoY), operating income of JPY 9,500 million (up 16.9% YoY), ordinary income of JPY 11,000 million (up 36.3% YoY), and net income attributable to owners of parent of JPY 8,400 million (up 47.8% YoY), with no revisions made.